Optimus Drugs Private Limited

Optimus Drugs is a Contract Development and Manufacturing Organization (CDMO) specializing in small molecule pharmaceuticals. The company offers integrated, end-to-end solutions spanning drug substance intermediates, drug substance (APIs), drug product intermediates, and finished drug products including oral solids, semi-solids, and controlled-release formulations.

Service Portfolio:

• Drug Substance Intermediates: custom synthesis, scale-up, cGMP/non-GMP manufacturing from clinical to commercial scale
• Drug Substance: small molecule API development and manufacturing across NCE/NDA, custom APIs, and generic APIs
• Drug Product Intermediates: pellets, micronized APIs, spray-dried materials
• Drug Product: oral solids, semi-solids, immediate and controlled-release formulations with seamless tech transfer support

Regulatory & Quality: The company maintains GMP-certified manufacturing with successful audits by USFDA, EU GMP, ANVISA, WHO, TGA, and EDQM. Founded in 2004 as a custom synthesis laboratory, Optimus has grown into a globally recognized pharmaceutical manufacturer with a strong presence across the small molecule value chain.

Therapeutic Focus: Manufactures products across Diabetes, Cardiac, Neurology, Anti-bacterial, and Anti-fungal therapies. The company is majority-owned by Sekhmet Pharmaventures (acquired May 2022), part of the Gamot API platform based in Singapore.